A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
| Status: | Completed |
|---|---|
| Conditions: | Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 45 - Any |
| Updated: | 4/2/2016 |
| Start Date: | January 2012 |
| End Date: | July 2012 |
| Contact: | Marie Wesselhoft |
| Email: | mwesselhoft@msdx.co |
A Longitudinal Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients
before and after beginning Natalizumab.
before and after beginning Natalizumab.
Inclusion Criteria:
1. Diagnosis of clinically definite relapsing remitting MS (RRMS)
2. Age 45 years and older
3. Willing and able to provide written informed consent
4. Patient has high disease activity.
5. Patient is about to begin Natalizumab (Tysabri) therapy.
Exclusion Criteria:
1. Any clinically significant disease other than MS that is likely to interfere with the
evaluation of CDMS
2. Known infectious or hematological disease.
3. Unwilling or unable to comply with the requirements of this protocol
4. Subject can not have a gadolinium enhanced MRI
We found this trial at
1
site
Click here to add this to my saved trials
